1 Scopus citations


The FDA has approved CAR-T cell therapy for the treatment of B cell malignancies. Despite the clinical success of CD19 targeted CAR-T, several barriers limit the wider adoption of CAR-based therapies as viable long-term cancer therapies. Many of the barriers that limit the routine use of CAR-T cell therapies stem from utilizing autologous patient T cells as the starting material to generate CAR-T. Here we will describe the limitations of autologous CAR-T, the advantages and hurdles of allogeneic donor CAR-T, the learnings from clinical trials using allogeneic CART19 and discuss the future direction of the field.

Original languageEnglish
Title of host publicationCancer Drug Discovery and Development
PublisherHumana Press Inc.
Number of pages12
StatePublished - 2022

Publication series

NameCancer Drug Discovery and Development
ISSN (Print)2196-9906
ISSN (Electronic)2196-9914


  • Allogeneic CAR-T
  • Allogeneic cellular therapy
  • CAR-T
  • CRISPR/Cas9
  • Genetically edited donor derived CAR-T
  • Off the shelf CAR-T
  • TCRab deleted T cells
  • TRAC
  • UCART123
  • UCART19
  • UCART7
  • Universal CAR-T
  • β2-microglobulin (B2M)


Dive into the research topics of 'Off-the-Shelf CAR-T'. Together they form a unique fingerprint.

Cite this